Alnylam Pharmaceuticals Income Taxes Paid, Net increased by 85.5% to $2.37M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 20.2%, from $2.97M to $2.37M. Over 2 years (FY 2022 to FY 2024), Income Taxes Paid, Net shows an upward trend with a 132.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A lower cash tax rate relative to statutory rates can indicate effective tax planning, while high cash taxes may signal a lack of tax-efficient strategies or one-time tax events.
This metric represents the actual cash paid for income taxes during the period, net of any refunds received. It provides...
Standard supplemental disclosure; peers are compared based on their cash effective tax rate.
supplemental_income_taxes_paid_net| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $663.50K | $663.50K | $663.50K | $663.50K | $1.51M | $1.51M | $1.51M | $1.51M | $1.99M | $1.57M | $4.61M | $6.19M | $2.97M | $1.28M | $2.37M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +126.9% | +0.0% | +0.0% | +0.0% | +32.0% | -20.8% | +192.7% | +34.4% | -52.1% | -57.0% | +85.5% |
| YoY Change | — | — | — | — | +126.9% | +126.9% | +126.9% | +126.9% | +32.0% | +4.6% | +206.1% | +311.4% | +49.4% | -72.3% | -20.2% |